ICD-10-CM code · FY2027
E78.5 Hyperlipidemia, unspecified
BillableValid for claims as a specific diagnosis code
About E78.5
Ask EvidencePulse about hyperlipidemia
Answers from the published evidence, with every study linked. The question goes into the box; nothing is sent until you press Ask.
Coding notes for E78.5
No notes of its own; the notes below apply from the codes above it.
Also applies, from E78 Disorders of lipoprotein metabolism and other lipidemias
Excludes1 Not coded here: never report these together with this code (use the code given instead).
Block E70-E88 notes (apply to every code in it)
Excludes1 Not coded here: never report these together with this code (use the code given instead).
Excludes2 Not part of this condition, but a patient can have both: report both codes when both apply.
- Ehlers-Danlos syndromes (Q79.6-)
Chapter 4 notes (apply to every code in it)
Note
- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Related codes in E78
- E78.0 Pure hypercholesterolemiaHeader
- E78.1 Pure hyperglyceridemiaBillable
- E78.2 Mixed hyperlipidemiaBillable
- E78.3 HyperchylomicronemiaBillable
- E78.4 Other hyperlipidemiaHeader
- E78.6 Lipoprotein deficiencyBillable
- E78.7 Disorders of bile acid and cholesterol metabolismHeader
- E78.8 Other disorders of lipoprotein metabolismHeader
- E78.9 Disorder of lipoprotein metabolism, unspecifiedBillable
Latest research on hyperlipidemia
- Statin use after but not before breast cancer diagnosis is associated with improved mortality in hormone receptor-positive early breast cancer
- Statins do not increase breast cancer risk in postmenopausal women
- Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
- Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
- Mirum: Ctexli reduces cholesterol metabolite build-up in patients with cerebrotendinous xanthomatosis
Landmark trials from 2MM Classics
2MM+
Read the research behind every diagnosis
2MM+ gives you every study summary in full, Classics downloads of the landmark trials, EvidencePulse and HypeCheck, and ad-free reading.
See 2MM+ plans